Publications by authors named "Claudia Nunez-Torron Stock"
Survival after allogeneic transplantation according to pretransplant minimal residual disease and conditioning intensity in patients with acute myeloid leukemia.
Front Oncol
May 2024
Article Synopsis
- Pretransplant measurement of minimal residual disease (MRD) in acute myeloid leukemia (AML) patients undergoing hematopoietic stem cell transplantation (HSCT) impacts their prognosis, particularly in relation to conditioning intensity.
- * The study analyzed transplant outcomes of 118 AML patients, revealing that those with positive MRD (MRD+) before HSCT had significantly worse event-free survival (EFS) and higher relapse rates compared to those with negative MRD (MRD-).
- * Among patients treated with myeloablative conditioning (MAC), MRD- patients fared better in terms of EFS and overall survival, while those receiving reduced intensity conditioning (RIC) showed similar outcomes, regardless of MRD status.*
Patients with secondary acute myeloid leukemia undergoing allogeneic stem-cell transplant have inferior outcomes than de novo acute myeloid leukemia regardless minimal residual disease level by flow cytometry.
Hematol Oncol
October 2023
Article Synopsis
- Patients with secondary acute myeloid leukemia (s-AML) do not do as well after treatment compared to those with regular (de novo) acute myeloid leukemia (AML).
- A study compared 58 s-AML patients with 52 de novo AML patients who had a stem-cell transplant.
- The results showed that s-AML patients had a higher chance of health problems and dying after the transplant, especially if they weren’t in complete remission before the procedure.
Real-life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refractory/relapsed: A single-centre experience.
Clin Case Rep
July 2022
We report our experience with venetoclax/hypomethylating agents (Ven/HMA) in 8 AML patients not candidates for intensive CT or refractory/relapsed with limited treatment options. The response rate was 50%. Venetoclax was well-tolerated in 62.
View Article and Find Full Text PDFObjective: To measure adherence to cyclosporine, tacrolimus and sirolimus prophylaxis against secondary graft failure; cyclosporine, tacrolimus, sirolimus and mycophenolate prophylaxis against graft- versus-host disease; and posaconazole, voriconazole, valganciclovir prophylaxis against infection in patients undergo to transplantation of haematopoietic stem cells; and to analise the incidence of acute complications based on adherence.
Method: Retrospective observational study of patients who underwent allogeneic haematopoietic stem cell transplantation between May 2017 and May 2018. Analyses were carried out between 0 and +100 days post-engraftment.